(Q36446929)

14 August 2017

1 reference

title

The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

14 August 2017

0 references

0 references

2

Toshifumi Hibi

1 reference

14 August 2017

3

Mamoru Watanabe

1 reference

14 August 2017

1

Takanori Kanai

1 reference

PubMed ID

16610976

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

5

1 reference

14 August 2017

453-466

1 reference

Inflammatory bowel disease: etiology and pathogenesis.

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Sulfasalazine. Adverse effects and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

How to do without steroids in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Intensive intravenous regimen for severe attacks of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Medical therapy for ulcerative colitis 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Nutrition and Gastrointestinal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Can cyclosporine go it alone in severe ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Biochemical mechanisms of cyclosporine neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Role of cytokines in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Evolving knowledge and therapy of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Growth factors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

The production of cytokines by polymorphonuclear neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

The key role of macrophages in the immunopathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Neutrophils, nitrogen oxides, and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

The role of the lymphocyte and its products in the propagation of joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leucapheresis in severe rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Homeostatic expansion of T cells during immune insufficiency generates autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

The association between immunodeficiency and the development of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Advances in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Targeting T cell responses by selective chemokine receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Naive and memory T cells show distinct pathways of lymphocyte recirculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

The lymphatic system in body homeostasis: physiological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Dynamics of blood-borne CD8 memory T cell migration in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Dietary antigens as aggravating factors in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Intensive intravenous treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Neutrophil apoptosis is delayed in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Centrifugal leukocyte apheresis for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Treating ulcerative colitis without medications--"look mom, no drugs!"

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.5.453

21 January 2018

Identifiers

DOI

10.1517/14712598.6.5.453

1 reference

14 August 2017

1 reference

PubMed ID

16610976